During the last session, Protara Therapeutics Inc (NASDAQ:TARA)’s traded shares were 0.56 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $6.14, reflecting an intraday gain of 10.04% or $0.56. The 52-week high for the TARA share is $10.48, that puts it down -70.68 from that peak though still a striking 73.94% gain since the share price plummeted to a 52-week low of $1.60. The company’s market capitalization is $210.72M, and the average intraday trading volume over the past 10 days was 0.63 million shares, and the average trade volume was 2.29 million shares over the past three months.
Protara Therapeutics Inc (TARA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TARA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Protara Therapeutics Inc (TARA) registered a 10.04% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.04% in intraday trading to $6.14, hitting a weekly high. The stock’s 5-day price performance is 11.64%, and it has moved by 117.73% in 30 days. Based on these gigs, the overall price performance for the year is 182.95%. The short interest in Protara Therapeutics Inc (NASDAQ:TARA) is 2.74 million shares and it means that shorts have 14.46 day(s) to cover.
Protara Therapeutics Inc (TARA) estimates and forecasts
Statistics show that Protara Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Protara Therapeutics Inc (TARA) shares have gone up 196.62% during the last six months, with a year-to-date growth rate less than the industry average at 16.25% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 39.98%. While earnings are projected to return 16.18% in 2025.
TARA Dividends
Protara Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Protara Therapeutics Inc insiders own 6.13% of total outstanding shares while institutional holders control 51.11%, with the float percentage being 54.45%. OPALEYE MANAGEMENT INC. is the largest shareholder of the company, while 45.0 institutions own stock in it. As of 2024-06-30, the company held over 2.3 million shares (or 20.1758% of all shares), a total value of $5.3 million in shares.
The next largest institutional holding, with 1.9 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 16.6361% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.95 million.
